Athira Pharma, Inc. Common Stock
Symbol: ATHA (NASDAQ)
4.02
▲ (2.16%) 0.085
Company Description:
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
Key Stats
- Today's Open: $3.89
- Today's High: $4.03
- Today's Low: $3.912
- Today's Volume: 1.09K
- Yesterday Close: $3.93
- Yesterday High: $4.2
- Yesterday Low: $3.85
- Yesterday Volume: 35.34K
- Last Min Volume: 18
- Last Min High: $4.015
- Last Min Low: $4.015
- Last Min VWAP: $4.015
Company Profile
- Name: Athira Pharma, Inc. Common Stock
- Website: https://www.athira.com
- Listed Date: 2020-09-18
- Location: BOTHELL, WA
- Market Status: Active
- CIK Number: 0001620463
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $16.80M
- Round Lot: 100
- Outstanding Shares: 3.94M
- Asset Type: CS
RECENT FILINGS FOR ATHA
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-10 | SCHEDULE 13G/A | View |
| 2025-10-03 | 8-K | View |
| 2025-09-11 | 8-K | View |
| 2025-08-07 | 10-Q | View |
| 2025-08-07 | 8-K | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-07-01 | 144 | View |
| 2025-07-01 | 144 | View |
| 2025-07-01 | 144 | View |
| 2025-07-01 | 144 | View |
| 2025-06-03 | 4 | View |
| 2025-06-03 | 4 | View |
| 2025-06-03 | 4 | View |
| 2025-06-03 | 4 | View |
| 2025-06-03 | 4 | View |
| 2025-06-03 | 4 | View |
Latest News on ATHA